Otovel is an otic anti-inflammatory and antibiotic drug owned by Laboratorios Salvat. This medication, which contains the active ingredients Ciprofloxacin Hydrochloride and Fluocinolone Acetonide, was first authorized for market use on 29 April, 2016.
The generic version of Otovel may become available after 24 March, 2030. This is due to the expiry of the patent US8932610, titled 'Aqueous clear solutions of fluocinolone acetonide for treatment of otic inflammation'.
The dual active components of Otovel make it effective in treating acute otitis media. Ciprofloxacin Hydrochloride acts as an antibiotic to combat the bacterial infection, while Fluocinolone Acetonide serves as an anti-inflammatory to reduce swelling and pain in the ear.
Otovel has a single patent, US8932610, which expires on 24 March, 2030. This patent, titled 'Aqueous clear solutions of fluocinolone acetonide for treatment of otic inflammation', inhibits the release of Otovel generic versions until it expires. Below are the details of the patent: